SNDY Solos Endoscopy Announces the MammoView(R) Br
Post# of 94143
Posted On: 11/07/2013 10:19:46 AM
SNDY Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
BOSTON, MA--(Marketwired - Nov 7, 2013) - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Increased awareness has resulted in more women receiving mammograms, the number of breast cancers detected, and the number of women receiving biopsies. Solos Endoscopy believes that as a result of awareness, breast cancers are being detected at an earlier, more treatable stage. Awareness efforts have successfully utilized marketing approaches to reduce the stigma associated with the disease.
However, more work needs to be done. As part of the new MammoView® Breast Cancer Global Initiative, Solos Endoscopy plans to team up with the various charities and foundations who are promoting "Breast Cancer Awareness" and educate them about the clinical benefits of the MammoView® instrument line and breast ductoscopy. The Solos Endoscopy MammoView® Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® instrument line allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"The MammoView® Breast Cancer Global Initiative is more than just awareness, it's about education, and choices for women. October is over; people and businesses nationwide will take down their pink ribbons and pink signs, yet women all over the world will still be battling breast cancer. Solos Endoscopy will continue its efforts to fight breast cancer not just in October but throughout the year," stated Robert Segersten, President of Solos Endoscopy.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
About Solos Endoscopy, Inc.:
Solos Endoscopy celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
Solos Endoscopy Announces the MammoView(R) Breast Cancer Global Initiative for 2014
BOSTON, MA--(Marketwired - Nov 7, 2013) - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Increased awareness has resulted in more women receiving mammograms, the number of breast cancers detected, and the number of women receiving biopsies. Solos Endoscopy believes that as a result of awareness, breast cancers are being detected at an earlier, more treatable stage. Awareness efforts have successfully utilized marketing approaches to reduce the stigma associated with the disease.
However, more work needs to be done. As part of the new MammoView® Breast Cancer Global Initiative, Solos Endoscopy plans to team up with the various charities and foundations who are promoting "Breast Cancer Awareness" and educate them about the clinical benefits of the MammoView® instrument line and breast ductoscopy. The Solos Endoscopy MammoView® Breast Endoscopy System can offer women a positive prognosis for recovery by detecting breast cancer up to six times faster than conventional methods. The MammoView® instrument line allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.
"The MammoView® Breast Cancer Global Initiative is more than just awareness, it's about education, and choices for women. October is over; people and businesses nationwide will take down their pink ribbons and pink signs, yet women all over the world will still be battling breast cancer. Solos Endoscopy will continue its efforts to fight breast cancer not just in October but throughout the year," stated Robert Segersten, President of Solos Endoscopy.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
About Solos Endoscopy, Inc.:
Solos Endoscopy celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719
(0)
(0)Scroll down for more posts ▼